Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 18/20 | 1.00 |
| ▸ | RARG | P13631 | 18/20 | 1.00 |
| ▸ | RARA | P10276 | 14/20 | 1.00 |
| ▸ | RXRA | P19793 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177444 | 1.00 | RARB (1.00) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL29836848 | 1.00 | RARB (1.00) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL345071 | 1.00 | RARB (1.00) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL9419009 | 0.95 | RARB (0.90) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL9418968 | 0.95 | RARB (0.90) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL5304297 | 0.92 | RARB (0.85) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL5304306 | 0.92 | RARB (0.85) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL12498687 | 0.92 | RARB (1.00) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL5304300 | 0.92 | RARB (0.85) | RARBRARGRARARXRAKDM4E | |
| Tromethamine SCHEMBL27599878 | 0.91 | RARB (0.82) | RARBRARGRARARXRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150342973-A1 | ANTIBIOTIC COMPOSITIONS AND RELATED SCREENING METHODS | ACADEMIA SINICA (TW) | 2015-12-03 | — | — | US | claimed |
| US-20110263046-A1 | Methods of identification of novel ligands for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (NR1F3) activity | PHENEX PHARMACEUTICALS AG (DE) | 2011-10-27 | — | — | US | claimed |
| EP-2349277-A2 | METHODS OF IDENTIFICATION OF NOVEL LIGANDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (NR1F3) ACTIVITY | Phenex Pharmaceuticals AG (DE) | 2011-08-03 | — | — | EP | claimed |
| US-20100144683-A1 | METHODS FOR GENERATING MAMMALIAN MODELS OF ATOPIC DISEASES, AND SCREENING FOR THEIR TREATMENT | ASSOCIATION POUR LA RECHERCHE A L'IGBMC (ARI) (FR) | 2010-06-10 | — | — | US | claimed |
| WO-2010049144-A2 | METHODS OF IDENTIFICATION OF NOVEL LIGANDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (NR1F3) ACTIVITY | PHENEX PHARMACEUTICALS AG (DE) | 2010-05-06 | — | — | WO | claimed |
| EP-2181710-A1 | Ligands for modulation of orphan receptor-gamma (NR1F3) activity | Phenex Pharmaceuticals AG (DE) | 2010-05-05 | — | — | EP | claimed |
| US-20090203641-A1 | ANTIBIOTIC COMPOSITIONS AND RELATED SCREENING METHODS | ACADEMIA SINICA (TW) | 2009-08-13 | — | — | US | claimed |
| EP-2046309-A2 | USE OF VITAMIN D3 AGONIST IN A MAMMALIAN MODEL FOR ATOPIC DISEASES AND OF VITAMIN D3 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DISEASES | Association pour la recherche à l'IGBMC (ARI) (FR) | 2009-04-15 | — | — | EP | claimed |
| EP-1891944-A1 | Use of Vitamin D3 agonist in a mammalian model for atopic diseases and of Vitamin D3 antagonists for the treatment of atopic diseases | Association pour la recherche à l'IGBMC (ARI) (FR) | 2008-02-27 | — | — | EP | claimed |
| WO-2008012645-A2 | USE OF VITAMIN D3 AGONIST IN A MAMMALIAN MODEL FOR ATOPIC DISEASES AND OF VITAMIN D3 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DISEASES | ASSOCIATION POUR LA RECHERCHE A L'IGBMC (ARI) (FR) | 2008-01-31 | — | — | WO | claimed |
| EP-1146901-A4 | POTENTIATION OF ANTI-CD38-IMMUNOTOXIN CYTOTOXICITY | RES DEV FOUNDATION (US) | 2002-05-08 | — | — | EP | claimed |
| EP-1146901-A1 | POTENTIATION OF ANTI-CD38-IMMUNOTOXIN CYTOTOXICITY | RESEARCH DEVELOPMENT FOUNDATION (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000040265-A1 | POTENTIATION OF ANTI-CD38-IMMUNOTOXIN CYTOTOXICITY | RESEARCH DEVELOPMENT FOUNDATION (US) | 2000-07-13 | — | — | WO | claimed |
| US-5824685-A | VISION DEFECTS AND GENE EXPRESSION | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1998-10-20 | — | — | US | claimed |
| EP-0465343-B1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CIRD GALDERMA (FR) | 1994-06-15 | — | — | EP | claimed |
| US-20260097083-A1 | METHOD FOR PRODUCING PANCREATIC ENDODERM CELLS | KYOTO UNIVERSITY (JP) | 2026-04-09 | — | — | US | disclosed |
| EP-4596675-A1 | METHOD FOR PRODUCING PANCREATIC ENDODERM CELLS | Kyoto University (JP) | 2025-08-06 | — | — | EP | disclosed |
| US-5587367-A | SYNERGISTIC EFFECT IN TREATING SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-12-24 | — | — | US | disclosed |
| WO-1996032935-A1 | INHIBITION OF APOPTOSIS IN CELLS EXPRESSING FAS-LIGAND FOLLOWING ACTIVATION | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-10-24 | — | — | WO | disclosed |
| US-5534261-A | Retinoid-based compositions and method for preventing adhesion formation using the same | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1996-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342973-A1 | ANTIBIOTIC COMPOSITIONS AND RELATED SCREENING METHODS | PGLS, MGAM, PTMA | RARB 4796/4885RARG 4776/4885RARA 4753/4885 |
| US-20090203641-A1 | ANTIBIOTIC COMPOSITIONS AND RELATED SCREENING METHODS | PGLS, MGAM, PTMA | RARB 4796/4885RARG 4776/4885RARA 4753/4885 |
| US-20260097083-A1 | METHOD FOR PRODUCING PANCREATIC ENDODERM CELLS | PNLIP, GIPR, CEL | RARB 1789/4885RARG 1947/4885RARA 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.